Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease

• Published in: Journal of blood medicine 2021-01, Vol.12, p.1045-1056
• Main Authors: Giraldo, Pilar, Andrade-Campos, Marcio
• Format: Article
• Language: English
• Subjects: Analysis; Anemia; Biomarkers; bleeding disorders; Blood; Bone marrow; Complications and side effects; Disease; Disease susceptibility; Enzymes; gaucher disease; haematologic manifestations; Hematology; Jewish people; long-term complications; Mass spectrometry; Morphology; Population; Review; Saccades (Eye movements); Scientific imaging; Spleen; Strategic planning (Business); Systematic review
• ISSN: 1179-2736; 1179-2736
• DOI: 10.2147/JBM.S279756

Gaucher disease (GD) is the most common lysosomal storage disorder. The principal manifestations for its diagnosis and further monitoring include haematological manifestations such as anaemia, thrombocytopaenia, spleen enlargement, and bleeding disorders, among others. This review aims to summarise and update the role of haematological complications in GD diagnosis and follow-up, describe their management strategies, and to use these indicators as part of the diagnostic approach. A systematic review following the recommendations of PRISMA-P 2020 was carried out. Publications indexed in the databases PubMed, Embase, Science Open, Mendeley, and Web of Science were electronically searched by three independent reviewers, and publications up to June 2021 were accessed. A total of 246 publications were initially listed, of which 129 were included for further review and analysis. Case reports were considered if they were representative of a relevant hematologic complication. From the first review dated in 1974 to the latest publication in 2021, including different populations confirmed that the haematological manifestations such as thrombocytopaenia and splenomegaly at diagnosis of GD type 1 are the most frequent features of the disease. The incorporation of haematological parameters to diagnosis strategies increases their cost-effectiveness. Hematologic parameters are part of the scoring system for disease assessment and the evaluation of therapeutic outcomes, providing reliable and accessible data to improve the management of GD. However, cytopaenia, underlying coagulation disorders, and platelet dysfunction need to be addressed, especially during pregnancy or surgery. Long-term haematological complications include the risk of neoplasia and immune impairment, an area of unmet need that is currently under research. Haematological features are key for GD suspicion, diagnosis, and management. Normalization of hematological parameters is achieved with the treatment; however, there are unmet needs such as the underlying inflammatory status and the long-term risk of hematologic neoplasia.